Table 2-1 Overview of the Status of Genetic Testing for Cancer

 

Molecular

Role in

Means of Detection

Disease

Target

Dx

Px

Tx

Established

Ready

Future

HEMATOLOGIC CANCER

CML

BCR-ABL

C

 

F

Cyto, SBlot, PCR

ISH

?Immuno

CLL

Trisomy 12

 

C

 

Cyto

ISH

 

ALL

B or T

AGRs

 

 

F

SBlot

 

PCR, RNase protection, denaturing gels

B

BCR-ABL

 

C

F

As in CML

 

 

 

t(1;19),(5;14), (8;14) (2;8),(8;22)

 

C

F

Cyto

PCR, ISH

 

 

other trans.

 

 

F

Cyto

 

SBlot, ISH, ?PCR

T

TCL5 rearr.

 

 

 

SBlot

PCR

 

 

t(14q 11),

 

 

F

Cyto

PCR

ISH

 

other trans.

 

 

 

Cyto

 

SBlot, ISH, ?PCR

AML

M2

t(8;21)

 

C

F

Cyto

 

ISH, SBlot, PCR

M3

t(15;17)

C

 

C

Cyto

SBlot

ISH, PCR

M4Eo

inv(16) or t(16;16)

C

C

F

Cyto

 

SBlot, ISH

AML with baso.

t(6;9)

 

C

F

Cyto

 

ISH, SBlot

AML with high plts.

inv(3) or t(3;3)

 

C

F

Cyto

 

SBlot, ISH, ?PCR

AML with-7 or-5

del 5 or 7

 

C

F

Cyto

ISH

 

Lymphoma

All cases

AGRs

C

 

F

Immuno, SBlot

 

PCR, RNase protection, denaturing gels

Follicular

t(14;18)

C

 

F

Cyto, SBlot, PCR

 

ISH

Burkitt's

t(8;14), t(8;22) t(2;8)

C

 

F

Cyto

SBlot, PCR

ISH



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement